Patent ID: 9488654
Filing Date: 2016-11-08
CPC Classification: A61P,G01N

Claim Text:
1. A method for determining whether a human subject with a triple-negative breast cancer will respond to therapy with a combination of bevacizumab (Avastin®), carboplatin, and paclitaxel, the method comprising: (a) obtaining a breast tumor sample from the human subject; (b) determining an expression profile in said sample of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein using a proximity immunoassay by contacting the sample with (1) capture antibodies that bind to each of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein, and (2) detection antibodies comprising first and second activation state-independent antibodies that bind to each of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein, wherein the capture antibodies are attached to a solid support, wherein the first activation state-independent antibodies are labeled with glucose oxidase, wherein the second activation state-independent antibodies are labeled with horseradish peroxidase, and wherein the binding of the first and second activation state-independent antibodies in proximity to each other generates a detectable signal; (c) comparing said expression profile to a reference expression profile comprising a median expression level of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein in a human population of triple-negative breast tumors; and (d) determining whether the human subject with a triple-negative breast cancer will respond to therapy with a combination of bevacizumab (Avastin®), carboplatin, and paclitaxel based on altered expression of VEGFR2 protein, c-KIT protein, HER1 protein, and IGF-1R protein in the sample relative to the reference expression profile, wherein decreased expression of VEGFR2 protein relative to the median expression level of VEGFR2 protein, decreased expression of c-KIT protein relative to the median expression level of c-KIT protein, increased expression of HER1 protein relative to the median expression level of HER1 protein, and decreased expression of IGF-1R protein relative to the median expression level of IGF-1R protein is indicative of response to therapy with the combination of bevacizumab (Avastin®), carboplatin, and paclitaxel.